{"id":"NCT03992846","sponsor":"Kissei Pharmaceutical Co., Ltd.","briefTitle":"Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain.","officialTitle":"A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled, Clinical Study to Assess the Efficacy and Safety of Linzagolix in Subjects With Moderate to Severe Endometriosis-associated Pain.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-06-13","primaryCompletion":"2021-10-18","completion":"2022-04-01","firstPosted":"2019-06-20","resultsPosted":"2024-05-29","lastUpdate":"2025-04-02"},"enrollment":486,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Endometriosis"],"interventions":[{"type":"DRUG","name":"75 mg linzagolix tablet","otherNames":[]},{"type":"DRUG","name":"200 mg linzagolix tablet","otherNames":[]},{"type":"DRUG","name":"Add-back capsule (E2 1 mg / NETA 0.5 mg)","otherNames":[]},{"type":"DRUG","name":"Placebo tablet to match 75 mg linzagolix tablet","otherNames":[]},{"type":"DRUG","name":"Placebo tablet to match 200 mg linzagolix tablet","otherNames":[]},{"type":"DRUG","name":"Placebo capsule to match Add-back capsule","otherNames":[]}],"arms":[{"label":"Linzagolix 75 mg","type":"EXPERIMENTAL"},{"label":"Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of this study is to demonstrate the efficacy and safety of linzagolix administered orally once daily for 3 months at a dose of 75 mg alone or of 200 mg in combination with add-back hormone replacement therapy (ABT: estradiol (E2) 1 mg / norethisterone acetate (NETA) 0.5 mg) versus placebo, in the management of moderate to severe endometriosis-associated pain (EAP).","primaryOutcome":{"measure":"Reduction of Dysmenorrhea (DYS) at Month 3 - Proportion of Responders","timeFrame":"Baseline to Month 3","effectByArm":[{"arm":"LGX 75 mg","deltaMin":44,"sd":null},{"arm":"LGX 200 mg+ABT","deltaMin":72.9,"sd":null},{"arm":"Placebo","deltaMin":23.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG001 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":71,"countries":["United States","Austria","Bulgaria","Czechia","France","Hungary","Poland","Romania","Spain","Ukraine"]},"refs":{"pmids":["38648863"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":160},"commonTop":["Headache","Hot flush","Fatigue","Anaemia","Nausea"]}}